Williams & Novak’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-10,489
Closed -$85.1K – 157
2026
Q2
$85.1K Sell
10,489
-150
-1% -$1.1K 0.06% 128
2026
Q1
$71.9K Buy
10,639
+79
+0.7% +$509 0.05% 122
2025
Q4
$62.8K Buy
+10,560
New +$56.1K 0.05% 132
2025
Q3
– Sell
-12,520
Closed -$42.9K – 151
2025
Q2
$42.9K Sell
12,520
-2,200
-15% -$7.02K 0.04% 129
2025
Q1
$43.1K Buy
+14,720
New +$46.1K 0.04% 119

Other funds holding PBYI

Williams & Novak's PBYI Position: Q3 2026 in Review

Williams & Novak sold out of Puma Biotechnology (PBYI) in Q3 2026, closing a stake of 10,489 shares — an estimated $85.1K sold.

Williams & Novak first reported a position in PBYI in Q1 2025 and held it in 5 quarters. The position peaked at $85.1K in Q2 2026. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.

  • Williams & Novak reported no remaining Puma Biotechnology position as of Q3 2026 after selling out during the quarter.
  • Williams & Novak sold 10,489 Puma Biotechnology shares in Q3 2026, an estimated $85.1K.
  • Williams & Novak first reported a position in Puma Biotechnology in Q1 2025 and held it in 5 quarters.
  • Williams & Novak's Puma Biotechnology position peaked at $85.1K in Q2 2026.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.

Based on Williams & Novak's 13F filing for Q3 2026, filed 9 Oct 2026.